Document:

Exhibit 10.4

 

FORM OF LETTER AGREEMENT

 

	 	[·],
    2017
	 	 
	Osprey Energy Acquisition Corp.	 
	1845 Walnut Street, 10th Floor	 
	Philadelphia, PA 19103	 

 

Re: Initial Public Offering

 

Gentlemen:

 

This letter (this “Letter Agreement”)
is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”)
to be entered into by and among Osprey Energy Acquisition Corp., a Delaware corporation (the “Company”),
and Credit Suisse Securities (USA) LLC as representative (the “Representative”) of the several underwriters
named therein (the “Underwriters”), relating to an underwritten initial public offering (the “Public
Offering”), of 28,750,000 of the Company’s units (including up to 3,750,000 units that may be purchased to
cover over-allotments, if any) (the “Units”), each comprised of one share of the Company’s Class A
common stock, par value $0.0001 per share (the “Common Stock”), and one-half of one warrant. Each whole
Warrant (each, a “Warrant”) entitles the holder thereof to purchase one share of Common Stock at a price
of $11.50 per share, subject to adjustment. The Units shall be sold in the Public Offering pursuant to a registration statement
on Form S-1 and prospectus (the “Prospectus”) filed by the Company with the Securities and Exchange
Commission (the “Commission”) and the Company shall apply to have the Units listed on the Nasdaq Capital
Market. Certain capitalized terms used herein are defined in paragraph 11 hereof.

 

In order to induce the Company and the Underwriters
to enter into the Underwriting Agreement and to proceed with the Public Offering and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Osprey Sponsor, LLC (the “Sponsor”) and
each of the undersigned individuals, each of whom is a member of the Company’s board of directors and/or management team
(each, an “Insider” and collectively, the “Insiders”), hereby agrees with the
Company as follows:

 

1.  The Sponsor and each Insider agrees
that if the Company seeks stockholder approval of a proposed Business Combination, then in connection with such proposed Business
Combination, it, he or she shall (i) vote any shares of Capital Stock owned by it, him or her in favor of any proposed Business
Combination and (ii) not redeem any shares of Common Stock owned by it, him or her in connection with such stockholder approval.

 

2.  The Sponsor and each Insider hereby
agrees that in the event that the Company fails to consummate a Business Combination within 24 months from the date of the closing
of the Public Offering, or such later period approved by the Company’s stockholders in accordance with the Company’s
amended and restated certificate of incorporation, the Sponsor and each Insider shall take all reasonable steps to cause the Company
to (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more
than 10 business days thereafter, subject to lawfully available funds therefor, redeem 100% of the Common Stock sold as part of
the Units in the Public Offering (the “Offering Shares”), at a per-share price, payable in cash, equal
to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account
and not previously released to the Company to pay its franchise and income taxes (less up to $100,000 of interest to pay dissolution
expenses), divided by the number of then outstanding Offering Shares, which redemption will completely extinguish all Public Stockholders’
rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and
(iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining
stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations
under Delaware law to provide for claims of creditors and other requirements of applicable law. The Sponsor and each Insider agrees
to not propose any amendment to the Company’s amended and restated certificate of incorporation that would modify the substance
or timing of the Company’s obligation to redeem 100% of the Offering Shares if the Company does not complete a Business Combination
within 24 months from the closing of the Public Offering, unless the Company provides its public stockholders with the opportunity
to redeem their shares of Common Stock upon approval of any such amendment at a per-share price, payable in cash, equal to the
aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not
previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding Offering Shares.

 

     

     

    

 

The Sponsor and each Insider acknowledges
that it, he or she has no right, title, interest or claim of any kind in or to any monies held in the Trust Account or any other
asset of the Company as a result of any liquidation of the Company with respect to the Founder Shares held by it, him or her. The
Sponsor and each Insider hereby further waives, with respect to any shares of Common Stock held by it, him or her, if any, any
redemption rights it, he or she may have in connection with the consummation of a Business Combination, including, without limitation,
any such rights available in the context of a stockholder vote to approve such Business Combination or in the context of a tender
offer made by the Company to purchase shares of Common Stock (although the Sponsor, the Insiders and their respective affiliates
shall be entitled to redemption and liquidation rights with respect to any Offering Shares it or they hold if the Company fails
to consummate a Business Combination within 24 months from the date of the closing of the Public Offering).

 

3.  Subject to the provisions set forth
in paragraphs 7(a) and (b) below, during the period commencing on the effective date of the Underwriting Agreement and ending 180
days after such date, the Sponsor and each Insider shall not, without the prior written consent of the Representative, (i) sell,
offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to
dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent
position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations
of the Commission promulgated thereunder, with respect to any Units, shares of Common Stock, Founder Shares, Warrants or any securities
convertible into, or exercisable, or exchangeable for, shares of Common Stock owned by it, him or her, (ii) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any
Units, shares of Common Stock, Founder Shares, Warrants or any securities convertible into, or exercisable, or exchangeable for,
shares of Common Stock owned by it, him or her, whether any such transaction is to be settled by delivery of such securities, in
cash or otherwise, or (iii) publicly announce any intention to effect any transaction specified in clause (i) or (ii).
Each of the Insiders and the Sponsor acknowledges and agrees that, prior to the effective date of any release or waiver of the
restrictions set forth in this paragraph 3 or paragraph 7 below, the Company shall announce the impending release or waiver by
press release through a major news service at least two business days before the effective date of the release or waiver. Any release
or waiver granted shall only be effective two business days after the publication date of such press release. The provisions of
this paragraph will not apply if the release or waiver is effected solely to permit a transfer of securities that is not for consideration
and the transferee has agreed in writing to be bound by the same terms described in this Letter Agreement to the extent and for
the duration that such terms remain in effect at the time of the transfer.

 

4.  In the event of the liquidation
of the Trust Account without the consummation of a Business Combination, Jonathan Z. Cohen (the “Indemnitor”)
agrees to indemnify and hold harmless the Company against any and all loss, liability, claim, damage and expense whatsoever (including,
but not limited to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any
litigation, whether pending or threatened, or any claim whatsoever) to which the Company may become subject as a result of any
claim by (i) any third party for services rendered or products sold to the Company or (ii) a prospective target business
with which the Company has entered into an acquisition agreement (a “Target”); provided, however,
that such indemnification of the Company by the Indemnitor shall apply only to the extent necessary to ensure that such claims
by a third party for services rendered (other than the Company’s independent public accountants) or products sold to the
Company or a Target do not reduce the amount of funds in the Trust Account to below (i) $10.00 per share of the Offering Shares
or (ii) such lesser amount per share of the Offering Shares held in the Trust Account due to reductions in the value of the
trust assets as of the date of the liquidation of the Trust Account, in each case, net of the amount of interest earned on the
property in the Trust Account which may be withdrawn to pay taxes, except as to any claims by a third party (including a Target)
who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s
indemnity of the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended.
In the event that any such executed waiver is deemed to be unenforceable against such third party, the Indemnitor shall not be
responsible to the extent of any liability for such third party claims. The Indemnitor shall have the right to defend against any
such claim with counsel of his choice reasonably satisfactory to the Company if, within 15 days following written receipt of notice
of the claim to the Indemnitor, the Indemnitor notifies the Company in writing that it shall undertake such defense.

 

    	 	2	 

     

    

 

5.  To the extent that the Underwriters
do not exercise their over-allotment option to purchase up to an additional 3,750,000 Units within 45 days from the date of the
Prospectus (and as further described in the Prospectus), the Sponsor agrees to forfeit, at no cost, a number of Founder Shares
in the aggregate equal to the product of 937,500 multiplied by a fraction, (i) the numerator of which is 3,750,000 minus the
number of Units purchased by the Underwriters upon the exercise of their over-allotment option, and (ii) the denominator of
which is 3,750,000. The forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the
Underwriters so that the Initial Stockholders will own an aggregate of 20.0% of the Company’s issued and outstanding shares
of Capital Stock after the Public Offering.

  

6.  (a)  The Sponsor and each Insider
(other than independent directors) hereby agrees not to participate in the formation of, or become an officer or director of, any
other blank check company unless the Company has failed to complete a Business Combination within 24 months after the closing of
the Public Offering. Such restriction does not preclude (i) the Sponsor from pursuing limited partnership interests in asset
management companies or (ii) any position as an officer or director of another blank check company held on the date hereof.
For the avoidance of doubt, the Sponsor and each Insider are allowed to participate in the formation of, or become an officer or
director of, another blank check company upon the Company entering into a definitive agreement with respect to a Business Combination.

 

(b)  The Sponsor and each Insider
hereby agrees and acknowledges that: (i) the Underwriters and the Company would be irreparably injured in the event of a breach
by such Sponsor or an Insider of its, his or her obligations under paragraphs 1, 2, 3, 4, 5, 6(a), 7(a), 7(b), and 9 of this Letter
Agreement (ii) monetary damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall
be entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity, in the event of
such breach.

 

7.  (a)  The Sponsor and each Insider
agrees that it, he or she shall not Transfer any Founder Shares (or shares of Common Stock issuable upon conversion thereof) until
the earlier of (A) one year after the completion of the Company’s initial Business Combination or (B) subsequent
to the Business Combination, (x) if the last sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted
for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading
day period commencing at least 150 days after the Company’s initial Business Combination or (y) the date on which the
Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all
of the Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property
(the “Founder Shares Lock-up Period”).

 

(b)  The Sponsor and each Insider
agrees that it, he or she shall not Transfer any Private Placement Warrants (or shares of Common Stock issued or issuable upon
the exercise of the Private Placement Warrants) until 30 days after the completion of a Business Combination (the “Private
Placement Warrants Lock-up Period”, together with the Founder Shares Lock-up Period, the “Lock-up Periods”).

 

(c)  Notwithstanding the provisions
set forth in paragraphs 7(a) and (b), Transfers of the Founder Shares, Private Placement Warrants and shares of Common Stock
issued or issuable upon the exercise or conversion of the Private Placement Warrants or the Founder Shares and that are held by
the Sponsor, any Insider or any of their permitted transferees (that have complied with this paragraph 7(c)), are permitted (a) to
the Company’s officers or directors, any affiliates or family members of any of the Company’s officers or directors,
any members of the Sponsor, or any affiliates of the Sponsor; (b) in the case of an individual, transfers by gift to a member
of the individual’s immediate family, to a trust, the beneficiary of which is a member of the individual’s immediate
family or an affiliate of such person, or to a charitable organization; (c) in the case of an individual, transfers by virtue
of laws of descent and distribution upon death of the individual; (d) in the case of an individual, transfers pursuant to
a qualified domestic relations order; (e) transfers by private sales or transfers made in connection with the consummation
of a Business Combination at prices no greater than the price at which the securities were originally purchased; (f) transfers
in the event of the Company’s liquidation prior to the completion of an initial Business Combination; (g) transfers
by virtue of the laws of the State of Delaware or the Sponsor’s limited liability company agreement upon dissolution of the
Sponsor; and (h) in the event of the Company’s liquidation, merger, capital stock exchange, reorganization or other
similar transaction which results in all of the Company’s stockholders having the right to exchange their shares of Common
Stock for cash, securities or other property subsequent to the completion of the Company’s initial Business Combination;
provided, however, that in the case of clauses (a) through (e), these permitted transferees must enter into a written agreement
agreeing to be bound by the restrictions herein.

 

    	 	3	 

     

    

 

8.  The Sponsor and each Insider represents
and warrants that it, he or she has never been suspended or expelled from membership in any securities or commodities exchange
or association or had a securities or commodities license or registration denied, suspended or revoked. Each Insider’s biographical
information furnished to the Company (including any such information included in the Prospectus) is true and accurate in all respects
and does not omit any material information with respect to the Insider’s background. The Sponsor and each Insider’s
questionnaire furnished to the Company is true and accurate in all respects. The Sponsor and each Insider represents and warrants
that: it, he or she is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order
or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; it, he
or she has never been convicted of, or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any financial
transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities and it, he or she
is not currently a defendant in any such criminal proceeding.

 

9.  Except as disclosed in the Prospectus,
neither the Sponsor nor any Insider nor any affiliate of the Sponsor or any Insider, nor any director or officer of the Company,
shall receive from the Company any finder’s fee, reimbursement, consulting fee, monies in respect of any repayment of a loan
or other compensation prior to, or in connection with any services rendered in order to effectuate the consummation of the Company’s
initial Business Combination (regardless of the type of transaction that it is), other than the following, none of which will be
made from the proceeds held in the Trust Account prior to the completion of the initial Business Combination: repayment of a loan
and advances up to an aggregate of $300,000 made to the Company by the Sponsor; reimbursement for any reasonable out-of-pocket
expenses related to identifying, investigating and consummating an initial Business Combination; and repayment of loans, if any,
and on such terms as to be determined by the Company from time to time, made by the Sponsor or any of the Company’s officers
or directors to finance transaction costs in connection with an intended initial Business Combination, provided, that, if the Company
does not consummate an initial Business Combination, a portion of the working capital held outside the Trust Account may be used
by the Company to repay such loaned amounts so long as no proceeds from the Trust Account are used for such repayment. Up to $1,500,000
of such loans may be convertible into warrants at a price of $1.00 per warrant at the option of the lender. Such warrants would
be identical to the Private Placement Warrants, including as to exercise price, exercisability and exercise period.

  

10.  The Sponsor and each Insider has
full right and power, without violating any agreement to which it is bound (including, without limitation, any non-competition
or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement and, as applicable, to
serve as a director on the board of directors of the Company and hereby consents to being named in the Prospectus as a director
of the Company.

 

11.  As used herein, (i) “Business
Combination” shall mean a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar
business combination, involving the Company and one or more businesses; (ii) “Capital Stock” shall
mean, collectively, the Common Stock and the Founder Shares; (iii) “Founder Shares” shall mean the
7,187,500 shares of the Company’s Class B common stock, par value $0.0001 per share, (or 6,250,000 shares if the over-allotment
option is not exercised by the Underwriters) held by the Initial Stockholders on the date hereof; (iv) “Initial
Stockholders” shall mean the Sponsor and any other holder of Founder Shares immediately prior to the Public Offering;
(v) “Private Placement Warrants” shall mean the warrants to purchase up to 7,000,000 shares of Common
Stock of the Company (or 7,750,000 shares of Common Stock if the over-allotment option is exercised in full) that the Sponsor has
agreed to purchase for an aggregate purchase price of $7,000,000 in the aggregate (or $7,750,000 if the over-allotment option is
exercised in full), or $1.00 per warrant, in a private placement that shall occur simultaneously with the consummation of the Public
Offering; (vi) “Public Stockholders” shall mean the holders of securities issued in the Public Offering;
(vii) “Trust Account” shall mean the trust fund into which a portion of the net proceeds of the
Public Offering and the sale of the Private Placement Warrants shall be deposited; and (vii) “Transfer”
shall mean the (a) sale or assignment of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any
option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of
a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section 16
of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder
with respect to, any security, (b) entry into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such
securities, in cash or otherwise, or (c) public announcement of any intention to effect any transaction specified in clause
(a) or (b).

 

    	 	4	 

     

    

 

12.  This Letter Agreement constitutes
the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings,
agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject
matter hereof or the transactions contemplated hereby. This Letter Agreement may not be changed, amended, modified or waived (other
than to correct a typographical error) as to any particular provision, except by a written instrument executed by all parties hereto.
Each Underwriter shall be an intended third-party beneficiary with respect to the provisions referenced in paragraph 6(b) of this
Letter Agreement, and such provisions and paragraph 6(b) may not be changed, amended, modified or waived without the consent of
the Representative.

 

13.  No party hereto may assign either
this Letter Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of the other
parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer
or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Sponsor and each Insider
and their respective successors, heirs and assigns and permitted transferees.

 

14.  This Letter Agreement shall be
governed by and construed and enforced in accordance with the laws of the State of New York applicable to contracts formed and
to be performed entirely within the State of New York, without giving effect to conflicts of law principles thereof that would
require or permit the application of the substantive laws of another jurisdiction. The parties hereto (i) all agree that any
action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced
in the courts of New York City, in the State of New York, and irrevocably submit to such jurisdiction and venue, which jurisdiction
and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent
an inconvenient forum.

 

15.  Any notice, consent or request
to be given in connection with any of the terms or provisions of this Letter Agreement shall be in writing and shall be sent by
express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or facsimile transmission.

 

16.  This Letter Agreement shall terminate
on the earlier of (i) the expiration of the Lock-up Periods or (ii) the liquidation of the Company; provided, however,
that this Letter Agreement shall earlier terminate in the event that the Public Offering is not consummated and closed by [                            ];
provided further that paragraph 4 of this Letter Agreement shall survive such liquidation.

 

[Signature Page Follows]

 

    	 	5	 

     

    

 

	 	Sincerely,
	 	 
	 	OSPREY SPONSOR, LLC
	 	 
	 	By:  	    
	 	Name: Jonathan Z. Cohen
	 	Title: Manager

 

	 	By:	 
	 	Name: Edward Cohen
	 	 	 
	 	By:	 
	 	Name: Jonathan Cohen
	 	 	 
	 	By:	 
	 	Name: Daniel Herz
	 	 	 
	 	By:	 
	 	Name: Jeffrey Brotman

 

	Acknowledged and Agreed:	 
	 	 
	OSPREY ENERGY ACQUISITION CORP.	 
	 	 
	 	 
	Name:	Jeffrey Brotman	 
	Title:	Chief Financial Officer, Chief Legal Officer and Secretary	 

 

 

[Signature Page to Letter Agreement]

 

 

6Exhibit 10.1

 

SUBSCRIPTION
AGREEMENT

 

Applied
DNA Sciences, Inc.

50
Health Sciences Drive

Stony
Brook, New York 11790

 

Gentlemen and Ladies:

 

The undersigned (the
“Subscriber”) hereby subscribes for ______________ shares (the “Shares”) of common stock, par value $0.001
per share (“Common Stock”), of Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), at a
cash purchase price per share of $1.76 (the “Purchase Price”), which represents the greatest of (i) $1.00, (ii) the volume-weighted
average closing price  at the end of each trading day of the Common Stock on the NASDAQ Capital Market for
the period from June 21, 2017 through June 27, 2017) and (iii) the closing bid price of the Common Stock on the NASDAQ Capital
Market on June 27, 2017, for an aggregate purchase price of $_____________. 
The Subscriber is one of several persons subscribing for Common Stock on or about the date hereof, but each such person may elect
to have a different Payment Date (as defined below).

 

1.                    Subscription.
Subject to the terms and conditions hereof, the Subscriber agrees to pay $________ by check or wire transfer of immediately available
funds as consideration (the “Payment”) for the Subscriber’s Shares. Subscriber agrees that the Payment shall
be made within 30 days of the date hereof (the date of such payment, the “Payment Date”). Subscriber agrees
that regardless of the date of the Payment Date, the Purchase Price will not change. The Subscriber acknowledges and agrees that
this subscription is irrevocable by the Subscriber but is subject to acceptance by the Company. The Subscriber agrees that it will
have no rights as a holder of Common Stock until the Payment is received by the Company.

 

2.                    Subscription
Compliance. The Subscriber agrees that this subscription is subject to the following terms and conditions:

 

The Company shall have the right, in its
sole discretion, to: (i) accept or reject this subscription; (ii) determine whether this Subscription Agreement has been properly
completed by the Subscriber and (iii) determine whether the Subscriber has met all of the Company’s requirements for investment
in the Shares. If the Company deems this subscription to be defective, deficient or otherwise non-compliant with the terms of this
offering, the Subscriber’s funds will be returned promptly to the Subscriber without interest or deduction.

 

3.                    Receipt
of Information.

 

a.                    The
Subscriber and Subscriber’s purchaser representative, if any, have reviewed a copy of the Company’s most recent Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K. The Subscriber, either alone or together with
Subscriber’s purchaser representative, if any, have such knowledge and experience in financial and business matters as to
be able to evaluate the merits and risks of an investment in the Company. Since May 11, 2017, the date of filing of the Company’s
most recent Quarterly Report on Form 10-Q, there has been no material adverse change in the business, properties, or results of
operations of the Company.

 

    	 	 	 

     

    

 

b.                    The
Subscriber and Subscriber’s representative, if any, have had the opportunity to ask questions of and receive answers from
the Company concerning the terms and conditions of the offering of the Shares by the Company and to obtain any additional information
Subscriber has requested which is necessary to verify the accuracy of the information furnished to the Subscriber concerning the
Company and such offering.

 

4.                    Representations
of Subscriber. In connection with the purchase of the Shares, the Subscriber hereby represents and warrants to the Company
as follows:

 

a.                    The
Subscriber is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act
of 1933, as amended (the “Act”).

 

b.                    The
Shares are being purchased for the Subscriber’s own account without the participation of any other person, with the intent
of holding the Shares for investment and without the intent of participating, directly or indirectly, in a distribution of the
Shares and not with a view to, or for a resale in connection with, any distribution of the Shares or any portion thereof, nor is
the undersigned aware of the existence of any distribution of the Company’s securities. Furthermore, the undersigned has
no present intention of dividing such Shares with others or reselling or otherwise disposing of any portion of such Shares, either
currently or after the passage of a fixed or predeterminable period of time, or upon the occurrence or nonoccurrence of any predetermined
event or circumstance.

 

c.                    The
Subscriber has no need for liquidity with respect to his purchase of the Shares and is able to bear the economic risk of an investment
in the Shares for an indefinite period of time and is further able to afford a complete loss of such investment.

 

d.                    The
Subscriber represents that his financial commitment to all investments (including his investment in the Company) is reasonable
relative to his net worth and liquid net worth.

 

e.                    The
Subscriber recognizes that the Shares will be sold to the Subscriber without registration under any United States federal or other
law relating to the registration of securities for sale.

 

f.                     The
Subscriber is aware that any resale of the Shares cannot be made except in accordance with the registration requirements of the
Act or an exemption therefrom.

 

g.                    The
Subscriber represents and warrants that all offers and sales of the Shares shall be made pursuant to an exemption from registration
under the Act or pursuant to registration under the Act, and the Subscriber will not engage in any hedging or short selling transactions
with regard to the Shares.

 

h.                    The
Subscriber is not acquiring the Shares based upon any representation, oral or written, by any person with respect to the future
value of, or income from, the Shares but rather upon an independent examination and judgment as to the prospects of the Company.

 

    	 	2	 

     

    

 

i.                     The
Subscriber understands that the Company has had a limited operating history, and as a result, its operations have produced limited
recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations
are subject to all the risks inherent in the establishment of a biotechnology company. The Subscriber appreciates and understands
the risks involved with investing in a Company with a limited operating history and has read and understands the risk factors and
other information set forth in the Company’s Annual Report on Form 10-K, filed on December 6, 2016, and the Quarterly Reports
on Form 10-Q for the quarterly periods ended December 31, 2016 and March 31, 2017 filed on February 9, 2017 and May 11, 2017, respectively.
These reports and any future filings made with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange
Act”), can be obtained by visiting the Securities and Exchange Commission’s website at http://www.sec.gov. The
Subscriber agrees that it is not relying on any other written information which may have been provided by the Company.

 

j.                     The
Subscriber represents, warrants and agrees that it will not sell or otherwise transfer the Shares without registration under the
Act or an exemption therefrom, and fully understands and agrees that the Subscriber must bear the economic risk of its purchase
because, among other reasons, the Shares have not been registered under the Act or under the securities laws of any state and,
therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Act and
under the applicable securities laws of such states, or an exemption from such registration is available. In particular, the Subscriber
is aware that the Shares are “restricted securities,” as such term is defined in Rule 144 promulgated under the Act
(“Rule 144”), and they may not be sold pursuant to Rule 144 unless all of the conditions of Rule 144 are met.

 

k.                    The
Company, by and through itself and/or legal counsel, has made no representations or warranties as to the suitability of the Subscriber’s
investment in the Company, the length of time the undersigned will be required to own the Shares, or the profit to be realized,
if any, as a result of investment in the Company. Neither the Company nor its counsel has made an independent investigation on
behalf of the Subscriber, nor has the Company, by and through itself and counsel, acted in any advisory capacity to the Subscriber.

 

l.                     The
Company, by and through itself and/or legal counsel, has made no representations or warranties that the past performance or experience
on the part of the Company, or any partner or affiliate, their partners, salesmen, associates, agents, or employees or of any other
person, will in any way indicate the predicted results of the ownership of the Shares.

 

m.                   The
Company has made available for inspection by the undersigned, and his purchaser representative, if any, the books and records of
the Company. Upon reasonable notice, such books and records will continue to be made available for inspection by investors upon
reasonable notice during normal business hours at the principal place of business of the Company.

 

n.                    The
Shares were not offered to the Subscriber by means of publicly disseminated advertisement or sales literature, nor is the Subscriber
aware of any offers made to other persons by such means.

 

    	 	3	 

     

    

 

o.                    All
information which the Subscriber has provided to the Company concerning the Subscriber is correct and complete as of the date set
forth at the end of this Subscription Agreement, and if there should be any material adverse change in such information prior to
receiving notification that this subscription has been accepted, the undersigned will immediately provide the Company with such
information.

 

5.                    Agreements
of Subscriber. The Subscriber agrees as follows:

 

a.                    The
sale of the Shares by the Company has not been recommended by any United States federal or other securities commission or regulatory
authority. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this Subscription
Agreement or of any of the Company’s filings with the Securities and Exchange Commission.

 

b.                    The
Shares will not be offered for sale, sold, or transferred other than pursuant to: (i) an effective registration under the Act or
in a transaction otherwise in compliance with the Act; and (ii) evidence satisfactory to the Company of compliance with the applicable
securities laws of other jurisdictions. The Company shall be entitled to rely upon an opinion of counsel satisfactory to it with
respect to compliance with the above laws.

 

c.                    The
Company is under no obligation to register the Shares or to comply with any exemption available for sale of the Shares without
registration, and the information necessary to permit routine sales of securities of the Company under Rule 144 of the Act may
not be available when you desire to resell them pursuant to Rule 144 of the Act. The Company is under no obligation to act in any
manner so as to make Rule 144 available with respect to the Shares . The Company is required to file periodic reports with the
Securities and Exchange Commission pursuant to Section 12(b) of the Exchange Act .

 

d.                    The
Company may, if it so desires, refuse to permit the transfer of the Shares unless the request for transfer is accompanied by an
opinion of counsel acceptable to the Company to the effect that neither the sale nor the proposed transfer will result in any violation
of the Act or the applicable securities laws of any other jurisdiction.

 

e.                    A
legend indicating that the Shares have not been registered under such securities laws and referring to the restrictions and transferability
of the Shares may be placed on the certificates or instruments delivered to the Subscriber or any substitutes thereof and any transfer
agent of the Company may be instructed to require compliance therewith.

 

6.                    Closing.
The Subscriber understands and agrees that the Company intends to issue the Shares upon receipt by the Company of this Subscription
Agreement, including the Confidential Prospective Purchaser Questionnaire, together with the Subscriber’s funds and certain
other documents to be delivered to the Company by Subscriber. The Subscriber further understands that there may be conditions to
closing this subscription which if not met may result in the return of this subscription hereunder.

 

7.                    Indemnification
of the Company. The undersigned understands the meaning and legal consequences of the representations and warranties contained
herein, and hereby agrees to indemnify and hold harmless, the Company, its respective agents, directors, officers, employees,
attorneys and affiliates from and against any and all damages, losses, costs and expenses (including attorneys’ fees) which
they or any of them may incur by reason of the failure of the Subscriber to fulfill any of the terms of this Subscription Agreement,
or by reason of any breach of the representations and warranties made by the Subscriber herein, or in any document provided by
the Subscriber to the Company.

 

    	 	4	 

     

    

 

8.                    Representative
Capacity. If an investment in the Company is being made by a corporation, partnership, trust or estate, the undersigned individual
signing on behalf of the Subscriber, represents that he has all right and authority, in his capacity as an officer, managing member,
managing partner, trustee, executor or other representative of such corporation, trust or estate, as the case may be, to make such
decision to invest in the Company and to execute and deliver this Subscription Agreement on behalf of such corporation, partnership,
trust or estate as the case may be, enforceable in accordance with its terms.

 

9.                    Subscription
Not Revocable. The undersigned hereby acknowledges and agrees that the undersigned is not entitled to cancel, terminate or
revoke this Subscription Agreement or any agreements of the undersigned hereunder and that this Subscription Agreement shall survive
the dissolution, death or disability of the undersigned.

 

10.                  Restrictions
on Transferability. The undersigned understands and agrees that the Shares shall not be sold, pledged, hypothecated or otherwise
transferred unless the Shares are registered under the Act and applicable state securities laws or an exemption from such registration
is available.

 

11.                  Governing
Law; Jurisdiction; Jury Trial. This Subscription Agreement is being delivered and is intended to be performed in the State
of New York, and shall be construed and enforced in accordance with the laws of such state which shall govern the rights of parties
without regard to conflict of laws principles. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that he or it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

 

12.                  Numbers
and Gender. In this Agreement, the masculine gender includes the feminine gender and the neuter and the singular includes the
plural, where appropriate to the context.

 

THIS SPACE INTENTIONALLY LEFT BLANK

 

    	 	5	 

     

    

 

CONFIDENTIAL
PROSPECTIVE PURCHASER QUESTIONNAIRE

 

This questionnaire is to be completed by
each accredited investor (“Accredited Investor”) as defined in Rule 501 promulgated under the United States
Securities Act of 1933, as amended (the “Securities Act”) who desires to purchase from Applied DNA Sciences,
Inc., a Delaware corporation (the “Company”), shares of the Company’s common stock, par value $0.001 per
share (“Shares”).

 

INSTRUCTIONS

 

This Questionnaire
is being given to the person who has expressed an interest in purchasing Shares of the Company. The purpose of this Questionnaire
is to determine whether you meet certain standards, because the Shares to be offered by the Company have not been, and will not
be, registered under the Securities Act.

 

If the answer to any
questions is “None” or “Not Applicable,” please so state.

 

Your answers will be
kept confidential at all times, however, you hereby agree that the Company may present this Questionnaire to such parties as it
deems appropriate in order to assure itself that the offer and sale of Shares to you will not result in violations of federal or
state securities laws which are being relied upon by the Company in connection with the offer and sale thereof.

 

INSTRUCTIONS: Please type or clearly
print your answer, and state “none” or “not applicable” when appropriate. Please complete Section A and
each other section you are requested to complete in Question A3. If there is insufficient space for any of your answers, please
attach additional pages. If the Shares are to be owned by more than one individual or by a corporation or partnership, you may
need extra copies of this Questionnaire. You may use photocopies or request extra copies from the Company.

 

SECTION A:  SUBSCRIBER INFORMATION

 

	A1.	Name(s) of Subscriber(s):	 
	 	 	 
	 	 	 

 

	A2.	Number of Shares:	 

 

	 	Subscribed for:  ________ Shares at a cash purchase price of $1.76 per share. 

 

	A3.	Manner of Ownership of Shares (please check below):  

 

	____	One Individual	Please complete Section A, B, C and, if applicable, D, E and F.

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 1

     

    

 

	____	Husband and Wife Tenants by the Entirety	Please have one spouse complete Sections A, B, C and if applicable, D, E and F. Please have both spouses complete Section C.
	 	 	 
	____	Tenants in Common	Please have each individual separately complete Sections A, B, and C and if applicable, D, E and F.
	 	 	 
	____	Joint Tenants with Right of Survivorship Two or More Individuals	Please have each individual separately complete Sections A, B, and C and if applicable, D, E and F.  (but not husband and wife)
	 	 	 
	____	Corporate Ownership	Please complete Sections A, B, D and, if applicable, E and F for the corporation.  Please have each person who owns an equity interest in the  corporation separately  complete Sections B and, if applicable, C, D, E and F.
	 	 	 
	____	Partnership Ownership	Please complete Sections A, B and D, and have each general partner and limited partner separately complete Sections B, C, D, E and F, if applicable.
	 	 	 
	____	Trust Ownership	Please complete Sections A, B and F, if applicable, and have each beneficiary and trustee of the trust separately complete Sections B, C, D, E and F, if applicable.

 

SECTION B:  ACCREDITED INVESTOR STATUS

 

	B1.	Please check one or more of the following definitions of “accredited investor,” if any, which applies to you.  If none of the following applies to you, please leave a blank.

 

	____ (a)	A Bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934 (the “Exchange Act”); an insurance company as defined in Section 2(13) of the Securities Act; an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that act; a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, or its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are Accredited Investors.

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 2

     

    

 

	____ (b)	A Private Business Development Company as defined in Section 202(a) (22) of the Investment Advisers Act of 1940.
	 	 
	____ (c)	An organization described in Section 501(c)(3) of the Internal Revenue Code or corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000.
	 	 
	____ (d)	A natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of purchase exceeds $1,000,000, excluding the value of the person’s primary residence.
	 	 
	____ (e)	A natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year.
	 	 
	____ (f)	Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D.
	 	 
	____ (g)	Any entity in which all of the equity owners are Accredited Investors.

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 3

     

    

 

SECTION C:  INDIVIDUAL INFORMATION

 

	C1.	General Information:

 

	 	Name:	 

 

		Age:	 	 	Social Security Number (if applicable):	 

 

	 	Marital Status:	 	 	Spouse’s Name:	 

 

If the Securities are to be owned by two
or more individuals (not husband and wife), are you related to any other co-owner(s)?

 

	 	Yes  _____   No  _____

 

	 	If yes, please explain the relationship(s):
	 	 
	 	 
	 	 
	 	 

 

	C2(a).	Principal Residence:

 

	 	Address:	 
	 	 	Number	Street

 

	 	 	 	 
	 	City	State/Province Country	Zip code

 

	 	Mailing Address (if other than Principal Residence above):

 

	 	 	 	 
	 	 	Number	Street

 

	 	 	 	 
	 	City	State/Province Country	Zip code

 

	Telephone Number:	(        )	-	 

 

	C2(b).	Have you ever resided in the United States (including its territories and possessions) or held a United States passport?

 

	 	Yes  _____   No  _____

 

	 	If yes, please explain where you lived, how long you lived there, or when you held the passport:

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 4

     

    

 

	C3.	Current Employment or Business Activity:

 

	 	Company Name:	 

 

 

	 	Address:	 
	 	 	Number	Street

 

	 	 	 	 
	 	City	State/Province Country	Zip code

 

	 	Principal Business:	 
	 	 	 
	 	Position and Title:	 

 

	 	Description of Duties and Responsibilities:  
	 	 
	 	 

 

	 	Length of Time in Present Position: 	 	 

 

	 	Is the company publicly owned?:     Yes  _____    No  _____

 

	C4.	Education:  Please describe your business and/or professional education or training, listing any schools you have attended and degrees you have received.

 

	Dates	 	Company Name

and Address	 	Principal Business	 	Description of Duties

and Responsibilities
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 5

     

    

 

	C5.	Prior Employment or Business Activity:  Please describe your prior employment or principal business activities during the last five years, providing all information requested below.

 

	Dates	 	Company Name

and Address	 	Principal

Business	 	Position &

Title	 	Description of

Duties and

Responsibilities
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

	C6.	The undersigned will provide a financial statement if requested by the Company.
	 	 
	C7.	Net worth, inclusive of the net worth of your spouse and inclusive of the value of your principal residence, furnishings therein and personal automobiles:

 

	 	(  ) less than $100,000	(  ) $100,000 to $199,999
	 	 	 
	 	(  ) $200,000 to $499,999	(  ) $500,000 to $1,000,000
	 	 	 
	 	(  ) over $1,000,000	 

 

	C8.	Net worth:  Your net worth, inclusive of the net worth of your spouse and excluding the value of your principal residence, furnishings therein and personal automobiles:

 

	 	(  ) less than $100,000	(  ) $100,000 to $199,999
	 	 	 
	 	(  ) $200,000 to $499,999	(  ) $500,000 to $1,000,000
	 	 	 
	 	(  ) over $1,000,000	 

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 6

     

    

 

	C9.	Indicate (a) your individual income from all sources for the calendar years 2016 and 2015 and estimated income for 2017 or (b) your joint income with your spouse from all sources for the calendar years 2016 and 2015 and estimated income for 2017:

 

	 	(a)	individual income:

 

	 	 	$ 60,000

to

$100,000	 	$100,001

to

$199,999	 	$200,000

to

$499,999	 	$500,000

and

over
	 	 	 	 	 	 	 	 	 
	2015	 	(   )	 	(   )	 	(   )	 	(   )
	 	 	 	 	 	 	 	 	 
	2016	 	(   )	 	(   )	 	(   )	 	(   )
	 	 	 	 	 	 	 	 	 
	2017 (est.)	 	(   )	 	(   )	 	(   )	 	(   )

 

	 	(b)	joint income:

 

	 	 	$ 60,000

to

$100,000	 	$100,001

to

$199,999	 	$200,000

to

$499,999	 	$500,000

and

over
	 	 	 	 	 	 	 	 	 
	2015	 	(   )	 	(   )	 	(   )	 	(   )
	 	 	 	 	 	 	 	 	 
	2016	 	(   )	 	(   )	 	(   )	 	(   )
	 	 	 	 	 	 	 	 	 
	2017 (est.)	 	(   )	 	(   )	 	(   )	 	(   )

 

	C10.	(a)          Was some portion of your income during your last taxable year taxed at the highest rate for income tax purposes?

 

_____  Yes         _____  No

 

	 	(b)          Do you anticipate that some portion of your income during your current taxable year will be taxed at the highest rate for income tax purposes?

 

_____  Yes         _____  No

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 7

     

    

 

	C11.	Investment experience:
	 	 	 
	 	(a)	The frequency with which you invest in marketable securities is:

 

	 	 	(   )  often	(   )  occasionally	(   )  never

 

	 	  (b)	The frequency with which you invest in unmarketable securities is:

 

	 	 	(   )  often	(   )  occasionally	(   )  never

 

SECTION D: CORPORATE OFFEREES OR PARTNERSHIP OFFEREES

 

	D1.	General Information

 

	 	Legal Name of Corporation or Partnership:	 

 

	 	 	 

 

	 	Fictitious name:	 

 

	 	 	 

 

	 	Country of Incorporation:	 

 

	 	Date of Incorporation:	 

 

	 	I.D. Number (if applicable):	 

 

	 	Fiscal Year Ends:	 

 

	 	Number of Equity Owners:	 

 

	 	Name and Title of Executive Officer Executing Questionnaire:	 

 

	 	 	 

 

	D2.	Business Address:	 

 

	 	 

 

	 	Mailing Address (if different):	 

 

	 	 

 

	 	Telephone Number:	(         )

 

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 8

     

    

 

Was the corporation or partnership
formed for the specific purpose of purchasing securities?

 

_____  Yes        _____  No

 

Check if applicable
to the corporation:

 

	 	Subchapter S _______________	Professional ________________

 

	D3.	The undersigned represents and warrants as follows:

 

		(a)	The corporation or partnership, as the case may be, has been duly incorporated or formed (if a
partnership), is validly existing as a corporation or partnership in good standing under the laws of the jurisdiction of its incorporation
or formation with full power and authority to enter into the transactions contemplated by the Subscription Agreement;

 

		(b)	(i)          The officers or partners of the undersigned
who, on behalf of the undersigned, have considered the purchase of the Shares and the advisers, if any, of the corporation or the
partnership, as the case may be, in connection with such consideration are named below in this Questionnaire, and such officers
and advisors or partners, if any, were duly authorized to act for the corporation or the partnership in reviewing such investment;

 

(ii)         The
names and positions of the officers or partners, of the undersigned who, on its behalf, have reviewed the purchase of the Shares
are as follows:

 

	 	 
	 	 
	 	 

 

(iii)        In
evaluating the merits and risks of the purchase of the Shares the corporation or the partnership, as the case may be, intends to
rely upon the advice of, or will consult with, the following persons:

 

	 	 
	 	 
	 	 
	 	 
	 	 

 

		(c)	The officers of the corporation (if not Accredited Investors) or the partners of the partnership
who, on its behalf, have considered the purchase of the Shares and the advisors, if any, of the corporation or the partnership
who, in connection with such consideration, together have such knowledge and experience in financial and business matters that
such officer(s), partner(s) and such advisor(s), if any, together are capable of evaluating the merits and risks of the purchase
of the Shares and of making an informed investment decision;

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 9

     

    

 

		(d)	Together with any corporation or group of corporations with which it files a consolidated federal
income tax return, the undersigned has reserves and/or net worth adequate to permit it to satisfy any tax or other liabilities
arising from its liability with respect to the investment and the operation thereof;

 

		(e)	The net worth of the corporation or the partnership is in excess of $__________________.

 

		(f)	The corporation or the partnership has had, during each of the past two fiscal or tax years, gross
income from all sources of at least $__________________ and $_____________________ respectively;

 

		(g)	The undersigned expects the corporation or the partnership to have during the current fiscal or
tax year, gross income from all sources of at least $_______________; and

 

		(h)	The undersigned knows of no pending or threatened litigation the outcome of which could adversely
affect the answer to any question hereunder;

 

		(i)	Indicate the following if a partnership offeree:

 

	 	(1)	The date the partnership was formed and state of

    formation:                                                                                                                                             
	 	 	 
	 	(2)	The names of each partner in the partnership:
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 10

     

    

 

Please have each individual partner execute
a separate Questionnaire.

 

	Section E:	Trust Offerees

 

	E1.	General Information:

 

	 	Legal Name:	 

 

	 	Country of Formation:	 

 

	 	Date of Formation:	 

 

	 	I.D. Number:	 	  Fiscal Year Ends:	 

 

	 	Number of Beneficiaries:	 

 

	 	Principal Purpose:	 

 

Was the trust
formed for the specific purpose of purchasing Securities?

 

_____  Yes        _____  No

 

Is any trustee
a United States person, as that term is defined in Rule 902(k) promulgated under the Securities Act?

 

_____  Yes        _____  No

 

	E2.	Business Address:	 

 

	 	 

 

	 	Telephone Number: 	(         )

 

	 	Mailing Address:	 

 

	 	 

 

	E3.	Authorization:  If the trust was established in connection with a deferred compensation plan, please attach a copy of the trust’s organizational documents and a properly certified copy of the resolutions adopted by the trust’s board of directors authorizing the trust to purchase the Shares and authorizing the trustee named below to execute on behalf of the trust all relevant documents necessary to subscribe for and purchase the Shares.  In all cases, please attach a properly certified copy of the resolutions adopted by the trustees of the trust authorizing the trust to purchase the Shares and authorizing the trustee named below to execute on behalf of the trust all relevant documents necessary to subscribe for and purchase the Shares.

 

	 	Name of Authorized Trustee:	 	 

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 11

     

    

 

	Section F:	Qualified Pension Plan (“Plan”) Offerees

 

	F1.	Please initial the appropriate space below:

 

	
        ________

        (initial)
	a.	The Plan requires the investment of each beneficiary or participant to be held in a segregated account and the Plan allows each beneficiary or participant to make his own investment decisions and, the decision to purchase the Shares has been made by the beneficiary or the participant and such beneficiary or participant is an Accredited Investor (Please have each such beneficiary or participant execute a separate Questionnaire)
	 	 	 
	 	 	OR
	 	 	 
	
        ________

        (initial)
	b.	The investment decisions made for the Plan are made by a plan fiduciary, whether a bank, an insurance company, or a registered investment advisor.
	 	 	 
	 	 	OR
	 	 	 
	
        ________

        (initial)
	c.	The Plan has total assets exceeding $5,000,000.

 

	F2.	General Information:

 

	 	Legal Name:	 

 

	 	Country of Formation:	 

 

	 	Date of Formation:	 

 

	 	I.D. Number:	 	  Fiscal Year Ends:	 

 

	 	Number of Beneficiaries:	 

 

	 	Principal Purpose:	 

 

	F3.	Business Address:	 

 

	 	 

 

	 	Telephone Number: 	(         )

 

	 	Mailing Address:	 

 

	 	 

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 12

     

    

 

	F4.	Authorization:  If the investment decision is being made by a beneficiary or participant of a Plan, please attach applicable trust documents which permit each beneficiary or participant to make his own investment decisions.  In all other cases, please attach a properly certified copy of the resolutions adopted by the trustees of the Plan trust authorizing the Plan to purchase the Shares and authorizing the fiduciary named below to execute on behalf of the Plan all relevant documents necessary to subscribe for and purchase the Shares.

 

	 	Name of Authorized Fiduciary:	 

 

	F5.	Is any beneficiary or participant of a Plan a United States person, as that term is defined in Rule 902(k) promulgated under the Securities Act?

 

_____  Yes        _____  No

 

THIS SPACE INTENTIONALLY LEFT BLANK; SIGNATURE
PAGE FOLLOWS

 

    	 	Confidential Prospective Purchaser Questionnaire
	Page 13

     

    

 

APPLIED DNA SCIENCES, INC.

SIGNATURE PAGE TO

QUESTIONNAIRE AND SUBSCRIPTION AGREEMENT

 

Your signature on this
Signature Page evidences your agreement to be bound by the Questionnaire and the Subscription Agreement.

 

The undersigned represents
that (a) he/she has read and understands this Subscription Agreement, (b) the information contained in this Questionnaire is complete
and accurate and (c) he/she will contact the Company immediately if any material change in any of this information occurs before
the acceptance of his/her subscription and will promptly sent the Company written confirmation of such change.

 

IN WITNESS WHEREOF, the
undersigned has executed this Questionnaire and Subscription Agreement on the date set forth below.

 

Date of Execution:      June 28,
2017

 

	 	FOR INDIVIDUALS:	 
	 	 	 
	 	 	 
	 	(Print Name)	 
	 	 	 
	Dated: June 28, 2017	 	 
	 	(Signature)	 
	 	 	 
	 	FOR CORPORATIONS:	 
	 	 	 
	 	 	 
	 	Name of Company	 
	 	 	 
	 	 	 
	 	Executive Officer of Company	 
	 	 	 
	Dated: _________, 2017	 	 
	 	Signature of Officer	 

 

    	 	 	 

     

    

 

	 	FOR PARTNERSHIPS:	 
	 	 	 
	 	 	 
	 	Name of Partnership	 
	 	 	 
	 	 	 
	 	Name of Partner executing	 
	 	Questionnaire	 
	 	 	 
	Dated: _________, 2017	 	 
	 	Signature of Partner	 
	 	executing Questionnaire	 
	 	 	 
	 	FOR TRUSTS:	 
	 	 	 
	 	 	 
	 	Name of Trust	 
	 	 	 
	 	 	 
	 	Name of Authorized Trustee	 
	 	Executing Questionnaire	 
	 	 	 
	Dated: _________, 2017	 	 
	 	Signature of Authorized	 
	 	Trustee	 
	 	 	 
	 	FOR QUALIFIED PENSION PLANS:	 
	 	 	 
	 	 	 
	 	Name of Qualified Pension Plan	 
	 	 	 
	 	and	 
	 	 	 
	 	 	 
	 	Name of Plan Fiduciary	 
	 	executing Questionnaire	 

 

    	 	 	 

     

    

 

	Dated: _________, 2017	 	 
	 	Signature of Plan Fiduciary	 
	 	executing Questionnaire	 
	 	 	 
	 	 	 
	 	 	 
	 	or	 
	 	 	 
	 	 	 
	 	Name of Plan Beneficiary	 
	 	executing Questionnaire	 
	 	 	 
	 	or	 
	 	 	 
	Dated: _________, 2017	 	 
	 	Signature of Plan Beneficiary	 
	 	executing Questionnaire	 

 

APPROVED THIS 28th DAY OF JUNE, 2017

 

APPLIED DNA SCIENCES, INC.

 

	By:	 	 
	 	Name:	 
	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]